ReviewBreast cancer research and treatment2019
Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).
Review in Breast cancer research and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 116 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Potential role of breast MRI to identify patients with high-risk lesions who might avoid surgery: a systematic review and meta-analysis.European radiology · 2026Pooled it
- Pathological Diagnosis, Work-Up and Reporting of Breast Cancer 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.Pathology oncology research : POR · 2022Pooled it
- Efficacy and Safety of Vacuum-Assisted Excision for Benign Breast Mass Lesion: A Meta-Analysis.Medicina (Kaunas, Lithuania) · 2021Pooled it
- Tor Vergata University-Hospital in the Beginning of COVID-19-Era: Experience and Recommendation for Breast Cancer Patients.In vivo (Athens, Greece) · 2020Guideline
- Intraductal papillary carcinoma of breast with invasion: A nomogram and survival from the analysis of the SEER database.Cancer medicine · 2023Trial
- Complex sclerosing lesions of the breast mimicking carcinoma: diagnostic pitfalls and the decisive role of immunohistochemistry.Annals of medicine and surgery (2012) · 2026Article
- Advancing Evidence of the Associations between specific Benign Breast Diagnoses and Future Breast Cancer Risk.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Is Surgical Excision Mandatory for Sclerosing Adenosis Diagnosed on Core Needle Biopsy? Multimodal Imaging Features and Upgrade Outcomes in a Symptomatic Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Management of Radial Scars and Complex Sclerosing Lesions of the Breast: To Excise or Not to Excise?World journal of surgery · 2026Article
- Reply to the Letter to the Editor: Potential role of breast MRI to identify patients with high-risk lesions who might avoid surgery-a systematic review and meta-analysis.European radiology · 2026Article
- Microdochectomy for patients with nipple discharge and the risk of associated breast cancer.BMC surgery · 2026Article
- Tomosynthesis-Guided Vacuum-Assisted Excision of B3 Breast Lesions: Reducing Overtreatment Without Compromising Safety.European journal of breast health · 2026Article
- Value of ultrasound-guided vacuum-assisted excision in the treatment of non-malignant breast nodules diagnosed as BI-RADS 4A or higher by ultrasound.Gland surgery · 2026Article
- Upgrade to malignancy after excision of MRI-only B3 breast lesions: should the size and histological type of the lesion be considered for therapeutic management?Insights into imaging · 2026Article
- Diagnostic Performance of Artificial Intelligence in Predicting Malignant Upgrade of B3 Breast Lesions: Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Review
- Variation in Pathological Appearance Across Repeated Sampling from Probably Benign Breast Lesions.Biomedicines · 2025Article
- Breast Lesions of Uncertain Malignant Potential and Risk of Breast Cancer Development: A Single-Center Experience on 10,531 Consecutive Biopsies.Medicina (Kaunas, Lithuania) · 2025Article
- [Modern surgical treatment of breast cancer. 5th Breast Cancer Consensus Conference].Magyar onkologia · 2025Article
- [Use of imaging methods in the current screening, diagnostics and treatment of breast cancer - Professional guidelines. 5th Breast Cancer Consensus Meeting (2025)].Magyar onkologia · 2025Article
- The role of the Kaiser score system in uncertain malignant potential (B3) breast lesions: a pilot study.Diagnostic and interventional radiology (Ankara, Turkey) · 2025Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe second International Consensus Conference on B3 lesions was held in Zurich, Switzerland, in March 2018, organized by the International Breast Ultrasound School to re-evaluate the consensus recommendations.
methodsThis study (1) evaluated how management recommendations of the first Zurich Consensus Conference of 2016 on B3 lesions had influenced daily practice and (2) reviewed current literature towards recommendations to biopsy.
resultsIn 2018, the consensus recommendations for management of B3 lesions remained almost unchanged: For flat epithelial atypia (FEA), classical lobular neoplasia (LN), papillary lesions (PL) and radial scars (RS) diagnosed on core-needle biopsy (CNB) or vacuum-assisted biopsy (VAB), excision by VAB in preference to open surgery, and for atypical ductal hyperplasia (ADH) and phyllodes tumors (PT) diagnosed at VAB or CNB, first-line open surgical excision (OE) with follow-up surveillance imaging for 5 years. Analyzing the Database of the Swiss Minimally Invasive Breast Biopsies (MIBB) with more than 30,000 procedures recorded, there was a significant increase in recommending more frequent surveillance of LN [65% in 2018 vs. 51% in 2016 (p = 0.004)], FEA (72% in 2018 vs. 62% in 2016 (p = 0.005)), and PL [(76% in 2018 vs. 70% in 2016 (p = 0.04)] diagnosed on VAB. A trend to more frequent surveillance was also noted also for RS [77% in 2018 vs. 67% in 2016 (p = 0.07)].
conclusionsMinimally invasive management of B3 lesions (except ADH and PT) with VAB continues to be appropriate as an alternative to first-line OE in most cases, but with more frequent surveillance, especially for LN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.